Ftse Mib
33.365,97
-0,52%
DAX
18.170,97
0,04%
S&P 500
5.477,90
0,16%
NASDAQ
17.805,16
0,49%
Bitcoin
61.104,27
0,48%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Plus Therapeutics Inc (PSTV) Plus Therapeutics Inc (PSTV) Notizie

PSTV

Plus Therapeutics (PSTV)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PSTV
DataOraFonteTitoloSimboloCompagnia
07/06/202423:02Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PSTVPlus Therapeutics Inc
07/06/202422:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTVPlus Therapeutics Inc
07/06/202413:30GlobeNewswire Inc.Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRITNASDAQ:PSTVPlus Therapeutics Inc
05/06/202413:26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PSTVPlus Therapeutics Inc
17/05/202423:00GlobeNewswire Inc.Plus Therapeutics Announces New Employment Inducement GrantsNASDAQ:PSTVPlus Therapeutics Inc
15/05/202422:15GlobeNewswire Inc.Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:PSTVPlus Therapeutics Inc
15/05/202422:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTVPlus Therapeutics Inc
13/05/202413:30GlobeNewswire Inc.Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024NASDAQ:PSTVPlus Therapeutics Inc
10/05/202413:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTVPlus Therapeutics Inc
09/05/202417:29GlobeNewswire Inc.Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE TrialNASDAQ:PSTVPlus Therapeutics Inc
08/05/202423:35GlobeNewswire Inc.Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE TrialNASDAQ:PSTVPlus Therapeutics Inc
06/05/202413:30GlobeNewswire Inc.Plus Therapeutics Announces Private Placement Financing of up to $18 MillionNASDAQ:PSTVPlus Therapeutics Inc
22/04/202413:00GlobeNewswire Inc.Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of DefenseNASDAQ:PSTVPlus Therapeutics Inc
08/03/202422:30Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PSTVPlus Therapeutics Inc
05/03/202422:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PSTVPlus Therapeutics Inc
22/11/202322:22Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PSTVPlus Therapeutics Inc
21/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PSTVPlus Therapeutics Inc
11/09/202313:00GlobeNewswire Inc.Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research ConferenceNASDAQ:PSTVPlus Therapeutics Inc
08/09/202313:00GlobeNewswire Inc.Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration AssayNASDAQ:PSTVPlus Therapeutics Inc
05/09/202313:00GlobeNewswire Inc.Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal MetastaseNASDAQ:PSTVPlus Therapeutics Inc
30/08/202313:00GlobeNewswire Inc.Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:PSTVPlus Therapeutics Inc
14/08/202322:05GlobeNewswire Inc.Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:PSTVPlus Therapeutics Inc
11/08/202312:30GlobeNewswire Inc.Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer ConferenceNASDAQ:PSTVPlus Therapeutics Inc
08/08/202322:05GlobeNewswire Inc.Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023NASDAQ:PSTVPlus Therapeutics Inc
08/08/202317:22GlobeNewswire Inc.Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer ConferenceNASDAQ:PSTVPlus Therapeutics Inc
03/08/202313:00GlobeNewswire Inc.Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceNASDAQ:PSTVPlus Therapeutics Inc
27/07/202322:05GlobeNewswire Inc.Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical OperationsNASDAQ:PSTVPlus Therapeutics Inc
27/07/202313:00GlobeNewswire Inc.Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer ConferenceNASDAQ:PSTVPlus Therapeutics Inc
13/07/202313:00GlobeNewswire Inc.Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals SummitNASDAQ:PSTVPlus Therapeutics Inc
29/06/202313:00GlobeNewswire Inc.Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual MeetingNASDAQ:PSTVPlus Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PSTV

La tua Cronologia

BIT
P1XQJ0
NLBNPIT1XQJ0 20240620 16...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network